Literature DB >> 12865598

Angiogenesis in endometrial carcinoma: correlation with survival and clinicopathologic risk factors.

Sema Ozuysal1, Tufan Bilgin, Hakan Ozan, H Filiz Kara, Hülya Oztürk, Ilker Ercan.   

Abstract

Association among angiogenesis, survival and clinicopathologic parameters in endometrial carcinoma was evaluated. Sixty patients who had been diagnosed as endometrial carcinoma, from 1993 to 1998, were included in the study. All patients had been surgically staged with bilateral pelvic and para-aortic lymph node dissection. All hysterectomy specimens were stained immunohistologically for factor VIII-related antigen. The area with the most intensified microvasculature was determined under low-power (x100) magnification, and the microvessel count of this area under high-power (x200) magnification was determined as the microvessel density (MVD) of the tumor. The mean MVD was 26.2 +/- 13.0 (range 6-68), and it was considered as high (n = 24; 40%), moderate (n = 19; 31.7%) and low (n = 17; 28.3%) when the MVD was >30, between 15-30 and <15, respectively. Statistical analysis included Mann-Whitney, Kruskal-Wallis and Spearman rank correlation tests. The Kaplan-Meier method was used to evaluate the difference between angiogenesis and survival. Multivariate analysis with the Cox regression model was used in MVD values and different clinicopathological parameters. There was positive correlation between MVD increase and surgicopathological stage (p < 0.05). A significant difference was seen between MVD increase and lymph node metastasis (p < 0.05). There were no differences between MVD and age, histological type, grade and lymphovascular invasion. MVD did not change in association with myometrial invasion depth. There was a significant difference in means of survival between the low and high MVD groups (p = 0.01). However, MVD was not an independent prognostic factor in multivariate analysis. Increased angiogenesis was found to be associated with advanced stage and decreased survival in endometrial carcinoma. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12865598     DOI: 10.1159/000071533

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  4 in total

Review 1.  Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.

Authors:  Laura Cerezo; Higinia Cárdenes; Helen Michael
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

2.  Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).

Authors:  Neesha C Dhani; Hal W Hirte; Lisa Wang; Julia V Burnier; Angela Jain; Marcus O Butler; Stephen Welch; Gini F Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J Wright; Amit M Oza
Journal:  Clin Cancer Res       Date:  2020-01-28       Impact factor: 12.531

3.  The Expression of VEGF and CD31 in Endometrial Lesions and Its Associations with Blood Flow Parameters of Transvaginal 3D Power Doppler Ultrasonography: A Preliminary Study.

Authors:  Meijuan Liu; Li Cai; Qifan Li; Xiaoran Chen; Lingyun Gao; Lei Jiang
Journal:  Cancer Manag Res       Date:  2020-11-04       Impact factor: 3.989

4.  VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis.

Authors:  Yong-Wen Huang; Li-Qun Xu; Rong-Zhen Luo; Xin Huang; Teng Hou; Yan-Na Zhang
Journal:  Reprod Biol Endocrinol       Date:  2013-05-21       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.